Actively Recruiting
Phase II Study of Oral Rifaximin to Improve Gut Microbiome and Outcomes After Stem Cell Transplant in Adults With Acute Leukemia
Led by Tata Memorial Centre · Updated on 2025-07-31
166
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effect of adding oral rifaximin tablets during allogeneic stem cell transplant ASCT in adults with acute leukemia. This randomized phase II study aims to see if rifaximin can improve the gut microbiome diversity and reduce risks such as death, infections, and graft versus host disease GVHD after transplant. The study also investigates immune system recovery and the impact of gut bacteria on immunity using advanced techniques like single-cell transcriptomics. Participants are randomly assigned to receive either rifaximin 200 mg tablets twice daily from 8 days before transplant to 60 days after, along with standard post-transplant care, or standard care alone. Standard care includes usual anti-GVHD treatments, antibiotics, and transfusions as needed. Stool and blood samples will be collected at various times to study changes in gut bacteria and immune cells, and gut biopsies may be analyzed if performed for GVHD. During the study, participants will have their gut microbial diversity measured about 14 days after transplant. Researchers will also assess outcomes like non-relapse mortality, severe acute GVHD, multidrug-resistant sepsis, and immune recovery over the following months up to one year. Safety and immune profiles will be monitored through blood tests, microbiome sequencing, and possibly tissue analysis. The study is expected to last until 2027, with ongoing evaluations throughout this period.
CONDITIONS
Brief Title
Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia
Research Team
D
Dr. Anant Gokarn, DM
D
Dr.Sumeet Mirgh, DM
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here